PDSB Stock Summary and Trading Ideas (PDS Biotechnology | NASDAQ:PDSB)

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.

PDS Biotechnology trades on the NASDAQ stock market under the symbol PDSB.

As of September 9, 2026, PDSB stock price was flat at $0.30 with 8,948,523 million shares trading.

PDSB has a beta of 3.64, meaning it tends to be more sensitive to market movements. PDSB has a correlation of 0.09 to the broad based SPY ETF.

PDSB has a market cap of $16.78 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PDSB traded as high as $6.85 and as low as $.20.

The top ETF exchange traded funds that PDSB belongs to (by Net Assets): VTI, VXF.

PDSB has underperformed the market in the last year with a return of -74.4%, while the SPY ETF gained +18.5%. In the last 3 month period, PDSB fell short of the market, returning -70.0%, while SPY returned +3.3%. However, in the most recent 2 weeks PDSB has outperformed the stock market by returning +35.4%, while SPY returned -0.6%.

PDSB support price is $.28 and resistance is $.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PDSB shares will trade within this expected range on the day.